News

The COVALENT-102 study has started BMF-219 treatment in patients with KRAS-mutated, advanced solid tumors.

In IMbrave050, the risk of disease recurrence or death was decreased with adjuvant atezolizumab and bevacizumab compared with active surveillance in patients with early-stage hepatocellular carcinoma.

Teon Therapeutics has entered into a clinical trial collaboration with Merck to assess TT-816 and pembrolizumab in a phase 1/2 study.

Gene G. Finley, MD, discusses how he envisions the treatment landscape of small cell lung cancer may evolve over the next 5-10 years.

Findings from a phase 1/2 trial showed that sotigalimab plus pembrolizumab led to antitumor activity and was well tolerated in the frontline setting of patients with metastatic melanoma.

Administering toripalimab with a platinum-based chemotherapy doublet around the time of surgery may extend event-free survival in patients with resectable non–small cell lung cancer.

Updated findings from the TACTI-002 trial of pembrolizumab and eftilagimod alpha in non–small cell lung cancer were presented during the Society for Immunotherapy of Cancer 37th Annual Meeting & Pre-Conference.

Preliminary data from the KYM901 trial of CMG901 revealed promising safety findings for patients with solid tumors. Full data will be presented at the upcoming 2023 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology.

Updated guidelines recommend olutasidenib as a targeted therapy for patients with relapsed/refractory acute myeloid leukemia with an IDH1 mutation.

Erika P. Hamilton, MD, discusses the findings from a phase 1 trial of DS-6000a in patients with advanced renal cell carcinoma and ovarian cancer.

According to findings from the phase 1 COBALT-RCC trial, CTX130 led to an objective response rate of 8%, a stable disease rate of 69%, and a disease control rate of 77% in patients with advanced clear cell renal cell carcinoma.

Months after the FDA granted accelerated approval to dostarlimab for this rectal cancer indication, phase 2 data have confirmed its efficacy and safety.

Based on the acceptance of its investigational new drug application by the FDA, the safety and tolerability of HT-001 will be evaluated in the phase 2a CLEER of patients with rash and skin disorders associated with EGFR inhibitor therapy.

In an interview with Targeted Oncology, Gayathri Ravi, MD, further discussed findings from a presentation at ASH 2022, and the role of minimal residual disease testing in multiple myeloma.

Following clearance by the FDA and AEMPS, the phase 2b VIRAGE trial of VCN-01 plus gemcitabine and nab-paclitaxel dosed its first patient with pancreatic ductal adenocarcinoma.

The ability to modify disease in patients with myelofibrosis was signaled in the REFINE study. The combination also displayed positive efficacy and was tolerable.

BXQ-350 in combination with modified FOLFOX7 and bevacizumab will be evaluated in a phase 1b/2 study of metastatic colorectal carcinoma.

Lucio Gordan, MD, has assumed the role of President & Managing Physician at Florida Cancer Specialists & Research Institute.

For cervical cancer awareness month, Lauren Bollinger, MD, discusses how the increase in research in the field of cervical cancer is driving the progress of treatment.

John M. Burke, MD, highlights progress in the field of hematology and oncology presented at the 64th American Society of Hematology Annual Meeting and Exposition.

In an interview with Targeted Oncology, Ariel Perez, MD, explained the outcomes of patients with R/R large B-cell lymphoma who were treated with Pola-BR in the real-world setting, and the key takeaways from a single-institution study.

Melanie Goldfarb, MD, MSc, FACS, FACE, FSSO, discusses the importance of survivorship and providing care to patients with thyroid cancer.

In an interview with Targeted Oncology, Jennifer R. Brown, MD, PhD, discussed the findings from the ALPINE study and the effectiveness of zanubrutinib when used for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

In an interview with Targeted Oncology, Ben Derman, MD, discussed data from an ongoing clinical trial evaluating MRD-guided discontinuation of maintenance therapy in patients with multiple myeloma.

In an interview with Targeted Oncology, Guenther Koehne, MD, PhD provided a detailed explanation on the impact of cytomegalovirus reactivation post-transplant, cytomegalovirus reactivation prevention, and refractory cytomegalovirus reactivation.

With the FDA clearing an investigational new drug application for HBM1020, the antibody can begin to be evaluated in clinical trials of patients with solid tumors.

In an interview with Targeted Oncology, Yazan Samhouri, MD, discussed new agents, clinical trials, and developments creating change in diffuse large B-cell lymphoma, as well as the key takeaways from ASH 2022.

The phase 1 study of ADXS-504 for the treatment of early prostate cancer is ongoing and new patients with be enrolled to test a higher dose level.

Findings from the phase 2 ROCKET trial showed a benefit in progression-free survival, overall survival, and overall response rate in patients with colorectal cancer treated with RRx-001 plus irinotecan.